The WynRisk Software tool was used to assist Peter Mac with the identification and monitoring of the Vincristine Drug Treatment.
Background
Vincristine is a medicine commonly used in the treatment of leukamias and lymphonas. It is neurotoxic and must only be administered intravenously. The key risk arises from situation in which Vincristine is mistaken for an intrathecal injection and as a result is administered into the cerebrospinal fluid, which is fatal in 85% of cases.
Sentinel events associated with the inadvertent intrathecal administration of Vincristine have been repeatedly reported in Australia and overseas.
WynRisk
Wyndarra Consulting completed a review of the Vincristine treatment for the Peter MacCallum Cancer Centre, a world leader in cancer treatment, research and education. WynRisk was used as the tool for identifying Vincristine risks, determining current controls in place and evaluating levels of controls in place.